{
    "clinical_study": {
        "@rank": "65312", 
        "acronym": "iTEP-CMT", 
        "brief_summary": {
            "textblock": "The aim of this study is to optimize pretargeting parameters using pharmacokinetic and\n      imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288\n      peptide in MTC patients with abnormal Ct serum level after initial complete surgery and at\n      least one abnormal lesion"
        }, 
        "brief_title": "ImmunoTEP for Patients With Medullary Thyroid Carcinoma.", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Medullary Thyroid Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Variation of TF2 molar dose, IMP-288 molar dose and pretargeting interval will be performed\n      in 4 to 5 cohorts of 3 patients, receiving 30 to 120 nmol of TF2 and 1.5 to 6 nmol of\n      peptides 1 to 3 days apart. Blood samples will be obtained after TF2 and 68Ga-IMP-288\n      injections.\n\n      A last cohort (cohorte number 5 or 6) with optimal conditions will be proposed. Whole-body\n      PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess\n      semi-quantitatively tumor targeting and tumor/background ratio. Moreover, the targeting\n      sensitivity of the TF2-pretargeted 68Ga-IMP-288 will be compared to standard methods of\n      tumor"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological diagnosis of CMT\n\n          -  Calcitonin> 150 pg / ml\n\n          -  Complete treatment of the primary tumor\n\n          -  at least one detectable lesion more than 10 mm on conventional imaging: bone lesions\n             can be taken into account if they extend outside of the bone and the party extra bone\n             is measurable.\n\n          -  Age \u2265 18 years\n\n          -  Negative pregnancy test for women of childbearing age in the previous 2 days\n             immuno-PET. Women of childbearing potential should use effective contraception take\n             continuously for 3 months.\n\n          -  KPS \u2265 70 or ECOG 0-1 and life expectancy of at least 6 months\n\n          -  Absence of serious illness or co-morbidity assessed risk\n\n          -  Creatinine \u2264 2.5 normal\n\n          -  Absence of cancer treatment within 6 weeks prior to the immuno-PET\n\n          -  No history of cancer within 5 years, except skin cancer other than melanoma or\n             carcinoma in situ of the cervix\n\n          -  Lack of anti-antibodies in patients who have previously received antibodies and\n             hypersensitivity to antibody or protein\n\n          -  Informed consent signed\n\n          -  Social Insurance\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breastfeeding\n\n          -  Serious illness or co-morbidity assessed risk\n\n          -  History of cancer within 5 years, except skin cancer other than melanoma or carcinoma\n             in situ of the cervix\n\n          -  Presence of anti-antibodies in patients who have previously received antibodies\n\n          -  Known hypersensitivity to antibody or protein\n\n          -  Need to establish a cancer treatment within 3 months of immuno-PET (before stock\n             evaluation 3 months)\n\n          -  Inability intellectual sign consent\n\n          -  Patient protected by law"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730638", 
            "org_study_id": "BRD 11/5-L"
        }, 
        "intervention": {
            "intervention_name": "\u2022 TF2 and 68 Ga-IMP-288", 
            "intervention_type": "Drug", 
            "other_name": [
                "\u2022 TF2: trivalent recombinant humanized antibody recognizing the ACE and the peptide histamine-succinyl-glycine IMP-288 (HSG)", 
                "\u2022 68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Bispecific"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "thyroid,", 
            "endocrine tumour", 
            "Nuclear medicine,", 
            "molecular imaging", 
            "ImmunoTEP"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ocouturier70@me.com", 
                    "last_name": "Olivier Couturier, PhD, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49100"
                    }, 
                    "name": "Angers Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier Couturier, PhD, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Vincent Rohmer, PU, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "francoise.bodere@chu-nantes.fr", 
                    "last_name": "fran\u00e7oise Bodere, PhD, MD", 
                    "phone": "00320240084136"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44100"
                    }, 
                    "name": "Nantes Hospital"
                }, 
                "investigator": {
                    "last_name": "Francoise Bodere, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "\"evelyne.cerato@chu-nantes.fr\" <evelyne.cerato@chu-nantes.fr>", 
                    "last_name": "Caroline Rousseau, PhD, MD", 
                    "phone": "0032240679931"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Sant Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'ouest, Ren\u00e9 Gauducheau"
                }, 
                "investigator": {
                    "last_name": "Caroline Rousseau, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.", 
        "other_outcome": {
            "measure": "tolerance", 
            "safety_issue": "Yes"
        }, 
        "overall_contact": {
            "email": "francoise.bodere@chu-nantes.fr", 
            "last_name": "Fran\u00e7oise Bodere, PhD, MD", 
            "phone": "00320240084136"
        }, 
        "overall_contact_backup": {
            "email": "evelyne.cerato@chu-nantes.fr", 
            "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
            "phone": "0032253482840"
        }, 
        "overall_official": {
            "affiliation": "Nantes Hospital", 
            "last_name": "Francoise Bodere, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : Agence National de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Decrease of TF2 and IMP- 288 molar doses and variation of pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 120 to 30 nmol of TF2 and 6 \u00e0 1.5 nmol of peptides 1 to 3 days apart.\nA last cohort (number 5 or 6)  with optimal conditions will be proposed Blood samples will be obtained after TF2 and 68Ga-IMP-288 injections. Whole-body PET images will be recorded 60 to 120 minutes after 68Ga-IMP-288 injection to assess semiquantitatively tumor targeting and tumor/background ratio.", 
            "measure": "Evaluation of the tumor targeting (No Unit) and signal/noise (No Unit)ratio by immunoTEP with TF2 and 68-Ga-IMP-288", 
            "safety_issue": "No", 
            "time_frame": "one week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730638"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Sensibilit\u00e9", 
            "safety_issue": "No", 
            "time_frame": "6 monts after immunoTEP"
        }, 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Immunomedics, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}